Supreme Court's Prior Ruling Challenges Trump Tariff Authority Framework
Prior Supreme Court decision against Trump's tariff powers under emergency act could challenge current pharmaceutical tariff order's legal foundation.
Event / Economy
President Trump signed an executive order establishing pharmaceutical tariffs up to 100% for companies without pricing agreements. Companies with favorable pricing deals and U.S. manufacturing investments receive 0% tariffs, while others face graduated rates. The order also modified metal tariffs and affected foreign pharmaceuticals from the EU, Japan, Korea, Switzerland, and the UK.
2026-08-19 to 2026-11-16 · UTC publication dates
Coverage begins 3 Apr, 02:37 UTC
Follow the documented timeline or explore the related reporting.
Under the updated metal tariff rules, products containing more than 15% metal by weight will face a 25% tariff on the entire product value. Products with metal content below 15% will only be subject to country-specific tariffs.
Pharmaceutical companies that sign a 'most favored nation' pricing agreement and actively build production facilities in the United States will be exempt from tariffs under the new executive order. The administration has already secured 17 pricing deals with major drugmakers, with 13 agreements signed.
Under trade frameworks reached with the U.S., the EU, Japan, Korea, and Switzerland will face a 15% tariff on patented pharmaceuticals. The United Kingdom will receive a 10% tariff rate, with the order noting this would reduce to zero under future trade agreements.
A February 20 Supreme Court ruling invalidated tariffs Trump imposed using the 1977 International Emergency Economic Powers Act, which had allowed him to immediately impose tariffs on any country at nearly any level. This decision limited Trump's tariff authority but did not prevent sectoral tariffs imposed under other legal provisions.
President Donald Trump signed an executive order that could impose pharmaceutical tariffs of up to 100% on patented drugs from companies that fail to reach pricing agreements with his administration within specified timeframes. Larger companies have 120 days to negotiate, while others have 180 days before the 100% tariffs would take effect.
Trump's administration announced changes to how tariffs on imported steel, aluminum, and copper will be calculated, effective Monday. The new approach bases tariff rates on the full customs value of what U.S. customers pay when buying foreign metal. Products fully made of these metals will continue to face 50% tariffs for most countries.
Trump imposed a 10% tariff on all imports using a separate legal power shortly after the Supreme Court's February ruling. This tariff can only remain in effect for 150 days, and more than two dozen states have challenged it.
Stephen J. Ubl, CEO of the pharmaceutical trade group PhRMA, cautioned that tariffs on cutting-edge medicines will increase costs and could jeopardize billions in U.S. investments in biopharmaceutical manufacturing. He noted that most medicines sourced from other countries come from reliable U.S. allies.
Prior Supreme Court decision against Trump's tariff powers under emergency act could challenge current pharmaceutical tariff order's legal foundation.
Trump imposes 25% tariff on metal-heavy products calculated by full customs value.
Executive order creates 0-100% pharmaceutical tariffs tied to pricing agreements and trading partners.